Leflunomide Is Safe and Effective for the Induction and Maintenance of Idiopathic Pulmonary Hemosiderosis Remission.
Pediatr Allergy Immunol Pulmonol
; 36(2): 62-67, 2023 06.
Article
em En
| MEDLINE
| ID: mdl-37267201
Objective: The present study was aimed to investigate the efficacy of leflunomide in idiopathic pulmonary hemosiderosis (IPH) disease control and glucocorticoid attenuation. Methods: The efficacy of leflunomide was determined based on disease control, safety, and glucocorticoid attenuation. Result: A total of 46 children with IPH were included in the present study. Of these 31 patients had been unsuccessfully treated with glucocorticoids before admission at our hospital and did not achieve complete remission; the other 15 patients had not previously received steroids. Leflunomide combined with glucocorticoid was administered to all patients, and all were followed up for a median duration of 3 years. The average hemoglobin level significantly increased and the median minimum steroid dose was significantly decreased after leflunomide administration. Conclusion: Leflunomide safely and effectively induced and maintained IPH remission and decreased IPH relapse and glucocorticoid dose.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hemossiderose
/
Pneumopatias
Limite:
Child
/
Humans
Idioma:
En
Revista:
Pediatr Allergy Immunol Pulmonol
Ano de publicação:
2023
Tipo de documento:
Article